# TAK-861 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tak-861

> The next catalyst for TAK-861, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TAK-861 |
| Codes | TAK-861 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | Narcolepsy Type 1 (NT1), [Narcolepsy Type 1](https://sec-api.dev/indications/narcolepsy-type-1) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 4, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Narcolepsy Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06505031 (A Study of TAK-861 in People With Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-07-16." https://clinicaltrials.gov/study/NCT06505031

### July 16, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Narcolepsy Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06505031 (A Study of TAK-861 in People With Narcolepsy Type 1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-07-16." https://clinicaltrials.gov/study/NCT06505031?tab=results

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07363720 (A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07363720

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07363720 (A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT07363720

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Narcolepsy Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05816382 (A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05816382

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Narcolepsy Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05816382 (A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT05816382

## Same indication

- [Alks 2680 dose 1](https://sec-api.dev/pdufa/alks-2680) (ALKS)
- [TAK-360](https://sec-api.dev/pdufa/tak-360) (TAK)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12), [February 2028](https://sec-api.dev/fda-calendar/2028-02)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tak-861.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TAK-861 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tak-861

```bibtex
@misc{secapidev_pdufa_tak_861_20261116,
  title        = {TAK-861 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tak-861}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tak_861_20261116","title":"TAK-861 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tak-861","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
